SCHEMBL4616255

SCHEMBL4616255

O=S(=O)(c1ccccc1)c1ccc(Cl)c(S(=O)(=O)N2CCC(N3CCCC3)CC2)c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.64
GAA P10253 3/20 0.64
ALDH1A1 P00352 8/20 0.57
POLB P06746 1/20 0.57
MBTD1 Q05BQ5 1/20 0.54
L3MBTL3 Q96JM7 1/20 0.54
HPGD P15428 1/20 0.52
CCR1 P32246 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
LMNA P02545 2/20 0.49
TSHR P16473 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
THRB P10828 1/20 0.49
HTT P42858 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
CXCR2 P25025 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956822 0.82 CCR1 (0.65) KDM4EGAAALDH1A1MBTD1L3MBTL3
SCHEMBL2963267 0.80 KDM4E (0.67) KDM4EGAAALDH1A1CCR1TSHR
SCHEMBL4618025 0.80 ALDH1A1 (0.53) KDM4EALDH1A1POLBL3MBTL1SMN1; SMN2
SCHEMBL6103435 0.78 ALDH1A1 (0.50) KDM4EALDH1A1POLBL3MBTL1SMN1; SMN2
SCHEMBL11964590 0.78 ALDH1A1 (0.74) KDM4EALDH1A1POLBHPGDL3MBTL1
SCHEMBL4618866 0.78 SFRP1 (0.49) KDM4EALDH1A1POLBL3MBTL1SMN1; SMN2
SCHEMBL6101940 0.77 POLB (0.46) KDM4EALDH1A1POLBL3MBTL1SMN1; SMN2
SCHEMBL6102007 0.77 SFRP1 (0.46) KDM4EALDH1A1POLBL3MBTL1SMN1; SMN2
SCHEMBL13089751 0.77 ALDH1A1 (0.52) KDM4EGAAALDH1A1POLBMBTD1
SCHEMBL6102020 0.74 SFRP1 (0.44) KDM4EALDH1A1POLBL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 KDM4E 3044/4885GAA 4113/4885ALDH1A1 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.